cemiplimab
sanofi,regeneron
['libtayo', '$regn']
$regn -announced 63% combined pathologic response rate for neoadjuvant libtayo monotherapy in stage ii to iv resectable cscc per primary analysis of a confirmatory phase 2 trial; data presented at esmo
My posts are my own.  Please do not use them for your investments, and please no disrespect!